Fw: DETOXIGENOMIC(tm) PROFILE LAUNCH

[Guest guest]

: ***SPECIAL ANNOUNCEMENT***

:

: -NEW GENOMIC TEST NOW AVAILABLE TO PRACTITIONERS

: -CAN REVEAL HIDDEN CAUSES OF ADVERSE DRUG REACTIONS, CHEMICAL

: SENSITIVITY & CHRONIC FATIGUE SYNDROMES

:

: For the first time, primary care practitioners can utilize a powerful

: new clinical tool to assess each patient's inborn ability to

: metabolize drugs, steroid hormones, and environmental toxins.

:

: Great Smokies Diagnostic Laboratory and GenovationsT are pleased to

: announce the launch of the new DetoxiGenomicT profile. This advanced

: profile is an extensive evaluation of over 20 genetic variations

: affecting Phase I and Phase II Detoxification and Oxidative

: Protection.

:

: Genetic analysis of Phase I and Phase II detoxification pathways is

: one of the most promising and fastest-growing areas in environmental,

: pharmaceutical, and genomic medicine. It offers the opportunity for

: diverse and powerful clinical applications, including risk

: identification and reduction for adverse drug reactions, chemical

: sensitivity, certain cancers, neurodegenerative disorders, and

: fatigue syndromes.

:

: " The detoxification system is the body's primary defense against

: 'foreign' chemicals entering the body, " explains Hanaway,

: M.D., GSDL Medical Director. " This new profile will allow doctors to

: identify potential genetic 'trouble spots' in this self-defense

: system early on, so they can design precise, individualized therapy

: to support detoxification and to avert health problems-as well as

: adverse reactions to medications and supplements-before they happen. "

:

: The potential clinical benefits are enormous. Adverse reactions to

: prescription drugs have been ranked as the fourth to the sixth

: leading cause of mortality in the U.S. Each year about 100,000

: Americans die from adverse reactions to pharmaceuticals-more than

: double the number killed in motor vehicle accidents. Annual hospital

: costs from these reactions have been estimated at between $1.5 to $4

: billion.

:

: " One gene evaluated in this new profile, CYP3A4, affects an enzyme

: the body uses to detoxify over 50% of all drugs-including many

: anti-depressants, steroid hormones, and lipid-lowering medications, "

: Dr. Hanaway points out. " Another, CYP2D6, affects an enzyme that

: metabolizes over 38% of drugs commonly cited in adverse drug reaction

: studies. "

:

: Besides being exposed to a growing variety of drugs, the human body

: is exposed to increasing toxic compounds in the environment,

: including pesticides, polycyclic aromatic hydrocarbons (eg, car

: exhaust, tobacco smoke), and solvents. Environmental factors are now

: generally believed to be involved in the causation of nearly all

: cancers; the World Health Organization has estimated that

: environmental factors constitute 25-33% of global disease burden.

:

: While other genetic assessments analyze isolated detoxification

: pathways involved in the processing of pharmaceuticals, the

: DetoxiGenomicT profile is a more comprehensive evaluation of over 20

: genetic variations affecting the patient's ability to detoxify food

: components, steroid hormones, medications, and environmental toxins.

:

: This will allow primary care physicians to individualize prevention

: and treatment strategies as they address conditions associated with

: chronic exposure to toxic substances, including multiple chemical

: sensitivity, neurodegenerative disorders, and chronic fatigue

: syndromes.

:

: The new DetoxiGenomicT profile is the latest addition to the

: GenovationsT line, which applies breakthroughs in genetic research to

: create innovative clinical assessment tools for primary care

: physicians to practice personalized medicine.

:

: GenovationsT tests measure individual genetic variations called

: single nucleotide polymorphisms. Under the influence of environmental

: triggers, these variations can make even a healthy person more prone

: to develop certain diseases or physiological imbalances. This allows

: physicians to implement customized preventive interventions earlier

: and with greater specificity, to reduce a patient's disease risk

: before symptoms appear.

:

: In addition to the DetoxiGenomicT profile, predictive genomic

: diagnostic profiles for cardiovascular health, bone health, and

: immune function are also available. Additional predictive genomic

: profiles for the primary care market will also be available soon.

:

: To order test kits, or to receive more information, visit

: http://www.genovations.com or call a Clinical Support Specialist at

: 800-522-4762.

:

: Great Smokies Diagnostic Laboratory http://www.gsdl.com provides

: advanced, innovative assessments of gastrointestinal, endocrine,

: immune, nutritional, and metabolic function to healthcare providers

: worldwide. GSDL's quality clinical laboratory services are licensed

: by Medicare and several state regulatory agencies, and accredited by

: the College of American Pathologists.